Adamis Pharmaceuticals Inc ADMP 0.9% may have a major catalyst on the way in the next several days. Adamis could be on the brink of a third ruling from the U.S. Food and Drug Administration related to its leading product candidate, a pre-filled epinephrine syringe that could serve as a low-cost alternative to the pricier EpiPen made byMylan N.V. MYL 0.11%.

The FDA has twice previously rejected Adamis’ product, once in March 2015 and once in June 2016. However, Adamis once again filed an NDA for the syringe in December after addressing concerns the FDA raised in the June rejection.

The FDA could have ruled on the pen as early as Wednesday, according to RTTNews.

If Adamis beats the odds and gains approval for its syringe, the stock certainly has plenty of short squeeze potential. However, if the syringe is rejected a third time, the prospects for Adamis’ leading product will be dimmer than ever.

Traders that aren’t afraid of volatility should look…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!